『Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection』のカバーアート

Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection

Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection

無料で聴く

ポッドキャストの詳細を見る
概要
 Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません